Model Number ZEPHYR 5.5-LP EBV |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Adult Respiratory Distress Syndrome (1696); Pneumothorax (2012)
|
Event Date 06/08/2020 |
Event Type
Death
|
Manufacturer Narrative
|
Pneumothorax is the most common side effect associated with the zephyr valve treatment (criner et al.A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate).Am j respir crit care med.2018; 198 (9): 1151-1164).Targeted lobar deflation likely causes inflation of the ipsilateral lobe, which can result in a tear of the already compromised parenchymal tissue of the emphysematous ipsilateral lobe, resulting in a pneumothorax (criner et al.A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate).Am j respir crit care med.2018; 198 (9): 1151-1164).In the liberate study (ide clinical study used to support pma p180002's approval), 26.6% of the zephyr valve subjects experienced a pneumothorax in the treatment period (less than or equal to 45 days).These were managed using standard of care procedures as per previously published guidelines (valipour, arschang, et al.Respiration 87.6 (2014): 513-521).In 17.4% of the events, the pneumothorax resolved without any additional intervention with subjects under careful observation.In over half the events (56.5%), the pneumothorax was managed with a chest-tube only.An additional 13% of the events were managed with a chest-tube and the temporary removal of one or more valves, while another 13% of the events were managed with a chest-tube and removal of all the implanted valves.Upon successful resolution of the pneumothorax, removed valves can be replaced.Patients that experienced a pneumothorax experienced clinical benefits of the zephyr valve treatment that were similar to the benefits experienced by patients who did not have a pneumothorax.The zephyr ebv system ifu and pulmonx training program both specifically reference pneumothorax as a known side effect of this procedure and the published guidelines (valipour, arschang, et al."expert statement: pneumothorax associated with endoscopic valve therapy for emphysema-potential mechanisms, treatment algorithm, and case examples." respiration 87.6 (2014): 513-521).The reported event aligns with the experience observed in the liberate clinical study and is an expected side effect to the zephyr valve treatment.
|
|
Event Description
|
On (b)(6) 2020, patient underwent bronchoscopic lung volume reduction with zephyr valve placement in the left upper lobe (lul) based on ct.A chartis assessment was performed in the lul and gave a negative collateral ventilation reading.Four zephyr valves were placed (4.0-lp ebv, 5.5-lp ebv, 5.5 ebv) in the lul.The patient had a pneumothorax two hours after the proceduring requiring a chest tube.On (b)(6) 2020, the pneumothorax had resolved, but the chest tube remained in the patient as a precaution.On (b)(6) 2020, the patient's condition worsened and the patient was intubated.The physician said it initially looked like acute respiratory distress syndrome and the patient had bilateral infiltrates.The physician did not believe the patient's condition was directly related to the zephyr valves.The air leak and pneumothorax had resolved.On (b)(6) 2020, the patient's valves were removed.On (b)(6) 2020, the patient was extubated, but was in poor condition on bilevel positive airway pressure.On (b)(6) 2020, the patient was sent to hospice care.On (b)(6) 2020, the patient passed away.
|
|
Search Alerts/Recalls
|
|